BDSI completes BEMA Buprenorphine Stage 3 trial in chronic pain BioDelivery Sciences International.

announced today that the last individual has finished the randomized part of its Phase 3 medical trial assessing the efficacy and basic safety of BEMA Buprenorphine for the treating moderate to serious chronic discomfort, signifying completion of the trial. We have been happy to have taken to completion our Stage 3 efficacy research for BEMA Buprenorphine in the administration of chronic discomfort, mentioned Dr. Andrew Finn, Executive Vice President of Item Development at BDSI. .. BDSI completes BEMA Buprenorphine Stage 3 trial in chronic pain BioDelivery Sciences International, Inc.She doesn’t want the federal government involved in things like calorie-counting. ‘They should stay out of our lives,’ she said. The AP-NORC Center study was conducted Nov. 21 through Dec. 14. It involved landline and cell phone interviews with 1, 011 adults nationwide and includes a margin of sampling error of plus or minus 4.2 %age points.

Antioxidants might help treat kids with celiac disease: Research A landmark research, conducted by researchers from the University of Belgrade, Serbia, and posted in the journal Clinical Biochemistry in 2009 2009, recommended that treatment with antioxidants might be able to decrease the symptoms of celiac disease significantly.